Cadila Health Care, NSE Symbol: CADILAHC, BSE Script Code: 532321, received final approval from United State Food and Drug Administration (USFDA) for Ursodiol Capsules USP, 300 mg (US RLD: Actigall Capsules). Ursodiol is also called gallstone dissolution agents. It is used for the treatment of primary biliary cirrhosis, an auto-immune liver disease.
The company also received tentative approval from the USFDA to market Linagliptin and Metformin Hydrochloride Tabs in the strengths of 2.5 mg/500 mg, 2.5 mg/850 mg, and 2.5 mg/1,000 mg. It is used along with diet and exercise to improve control of blood sugar levels in adults with type 2 diabetes mellitus.
Both drugs will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.